GHK-Cu: Five Decades of Copper Peptide Science

No research programme in the peptide catalogue has run longer than GHK-Cu’s: a tripeptide isolated from human plasma in the early 1970s, identified as a copper(II) complex before the decade was out, and still producing matrix-biology and cosmetic-science papers half a century later. It is also the molecule for which coordination chemistry — rather than sequence — drives nearly every practical decision at the bench.

How it was discovered

Its discovery was atypical for a peptide. Research in the early 1970s into why old liver tissue behaved unlike young tissue in culture led to a small-molecule factor in the albumin fraction of plasma. That factor turned out to be a tripeptide: glycyl-L-histidyl-L-lysine, or Gly-His-Lys. Together, the histidine imidazole, the free N-terminal amine and the amide nitrogen between them create a near-perfect binding site for copper(II), and the biologically relevant form was later shown to be the copper complex, not the free peptide.

Product specifications describe the complex: CAS 89030-95-5 and a molecular weight of 403.93 Da for GHK-Cu, compared with about 340.4 Da for GHK alone. The 63 Da gap represents copper plus coordination, and it is the value to look for on a mass spectrum to confirm that a vial holds the complex and not the apo-peptide. Vocabulary at copper peptide and tripeptide.

One observation from the early papers is repeated endlessly: plasma GHK levels fall considerably between early adulthood and later life. It is quoted everywhere and is best regarded as a historical measurement, not as a mechanism.

Coordination chemistry drives handling

In GHK-Cu the copper(II) ion adopts a roughly square-planar arrangement supplied by the histidine imidazole nitrogen, the terminal amino group and the deprotonated backbone amide nitrogen, while the lysine side chain and solvent complete its surroundings. Four practical consequences flow from this, and between them they account for most of the problems researchers run into with copper peptides.

• The colour tells you something. In solution the complex is a deep blue. If the colour fades or shifts, the coordination environment has changed — a genuinely helpful diagnostic that costs nothing.
• pH is more critical than with normal peptides. Deprotonation of the amide nitrogen depends on pH, so the complex is not equally stable at every pH. Strongly acidic conditions push it toward dissociation.
• Chelating agents compete. EDTA and comparable compounds will pull the copper away, as can some buffer ingredients. In cosmetic-science research, formulation compatibility is a true experimental variable.
• Reducing agents alter the oxidation state. Ascorbate converts Cu(II) toward Cu(I), a separate species with its own chemistry — a well-documented incompatibility in topical formulation work.

The redox activity works in the opposite direction too: a bound copper centre can catalyse oxidation of vulnerable residues in partners formulated alongside it, which is the compatibility issue in any multi-component blend that includes a copper peptide.

What studies have looked at

The gene-expression line of work needs a comment, because it is so often overstated. A much-quoted analysis found that GHK exposure altered the expression of many genes in cultured cells. That is a valid finding about the transcriptome of a cell culture; it does not demonstrate any systemic effect in a living organism, and the difference should be kept in view. Structural and mechanistic detail is in what is GHK-Cu.

The data most relevant to humans in the entire body of work are cosmetic: small, controlled studies of topical GHK-Cu formulations that reported changes in measured skin parameters. These are real human studies; they are also small, brief and tied to specific formulations, and they cannot be extrapolated to other routes.

How GHK-Cu compares with related molecules

AHK-Cu (copper tripeptide-3: Ala-His-Lys with copper) is the nearest analog and has been investigated more in the context of hair follicles than of the dermal matrix. Changing the single residue at position one alters the coordination environment slightly and the biology more than the structure would suggest. The comparison is set out in GHK-Cu vs AHK-Cu, with the analog available as AHK-Cu. Palmitoylated derivatives take yet another route, attaching a lipid tail to the GHK sequence for formulation purposes rather than to alter anything at receptor level.

Formats and practical lab points

GHK-Cu comes in bigger masses than most catalogue peptides — research vials of GHK-Cu hold 50, 100 and 200 mg — because its small molecular weight means a given number of moles weighs much less. At 403.93 Da, 50 mg equals about 124 µmol, around ten times as many molecules as 50 mg of a 4 kDa peptide would contain. Comparing a copper tripeptide with a bigger peptide by mass is therefore a serious calculation mistake.

Topical research formats include GHK-Cu face serum and GHK-Cu cream, where the formulation issues described above — pH, chelators, reductants, light exposure through the packaging — turn into the experiment itself rather than a side issue. Delivery considerations are covered in topical peptides in cosmetic research, the category in copper peptides, and class-level context in the skin research overview.

Why interest has endured

Half a century is a long time for a three-residue peptide to hold researchers’ attention. The explanation is that GHK-Cu occupies a crossroads: it is at once a peptide, a metal complex, a natural constituent of plasma and a formulation ingredient backed by real human cosmetic data. Hardly any other catalogue molecule ticks all four boxes. It is also a reminder that the metal is no add-on — take the copper away and you have a different molecule with a different body of literature.